AAPL327.36+0.77 (+0.23%) ▲|ABBV255.33+1.95 (+0.77%) ▲|ABT100.05-1.61 (-1.58%) ▼|ACN140.89-3.84 (-2.65%) ▼|ADBE226.71-8.03 (-3.42%) ▼|AMAT567.75+42.05 (+8.00%) ▲|AMD541.70+38.13 (+7.57%) ▲|AMGN364.49+0.32 (+0.09%) ▲|AMT163.75-3.32 (-1.98%) ▼|AMZN248.49-1.51 (-0.60%) ▼|AVGO386.17+8.01 (+2.12%) ▲|AXP351.03-0.90 (-0.26%) ▼|BA204.31-5.18 (-2.47%) ▼|BAC61.30+0.88 (+1.45%) ▲|BKNG177.97-1.48 (-0.82%) ▼|BLK1,040.96-13.15 (-1.25%) ▼|BMY60.47+0.31 (+0.51%) ▲|BNY158.67+1.74 (+1.11%) ▲|BRK-B489.69-1.56 (-0.32%) ▼|C132.90+4.18 (+3.25%) ▲|CAT889.71+25.41 (+2.94%) ▲|CL90.08-1.86 (-2.02%) ▼|CMCSA23.78-0.01 (-0.02%) ▼|COF206.12-0.65 (-0.31%) ▼|COP117.06+1.38 (+1.19%) ▲|COST931.02-4.78 (-0.51%) ▼|CRM170.24-3.55 (-2.04%) ▼|CSCO111.37+0.67 (+0.61%) ▲|CVS109.60+1.99 (+1.85%) ▲|CVX189.98+0.27 (+0.14%) ▲|DE589.47+3.47 (+0.59%) ▲|DHR178.69-22.42 (-11.15%) ▼|DIS96.50+0.09 (+0.09%) ▲|DUK125.59-0.26 (-0.21%) ▼|EMR139.43+2.85 (+2.09%) ▲|FDX314.80+8.58 (+2.80%) ▲|GD369.90-0.70 (-0.19%) ▼|GE340.98-0.33 (-0.10%) ▼|GEV1,083.23+4.05 (+0.38%) ▲|GILD129.80-3.41 (-2.56%) ▼|GM79.64+3.84 (+5.07%) ▲|GOOG348.19-3.18 (-0.91%) ▼|GOOGL348.89-3.10 (-0.88%) ▼|GS1,082.40+27.37 (+2.59%) ▲|HD330.63-2.41 (-0.72%) ▼|HON230.23+4.05 (+1.79%) ▲|IBM211.29-1.71 (-0.80%) ▼|INTC105.07+8.01 (+8.25%) ▲|INTU290.07-3.76 (-1.28%) ▼|ISRG357.26+4.09 (+1.16%) ▲|JNJ249.27+0.45 (+0.18%) ▲|JPM344.88+6.01 (+1.77%) ▲|KO82.09-0.04 (-0.04%) ▼|LIN506.73-5.32 (-1.04%) ▼|LLY1,163.31+16.41 (+1.43%) ▲|LMT505.40-4.14 (-0.81%) ▼|LOW203.42-1.29 (-0.63%) ▼|LRCX320.97+14.21 (+4.63%) ▲|MA538.78-8.66 (-1.58%) ▼|MCD265.19-2.45 (-0.92%) ▼|MDLZ59.79-0.49 (-0.80%) ▼|MDT82.31-0.98 (-1.18%) ▼|META647.02+1.17 (+0.18%) ▲|MMM169.90+10.79 (+6.78%) ▲|MO73.31-1.36 (-1.81%) ▼|MRK125.69+1.29 (+1.04%) ▲|MS215.36+4.42 (+2.10%) ▲|MSFT398.61-3.68 (-0.91%) ▼|MU974.66+109.20 (+12.62%) ▲|NEE87.92-0.08 (-0.09%) ▼|NFLX67.46-0.15 (-0.21%) ▼|NKE43.11-0.37 (-0.84%) ▼|NOW101.47-3.24 (-3.09%) ▼|NVDA206.09+2.81 (+1.38%) ▲|ORCL126.60+5.22 (+4.30%) ▲|PEP134.75-0.71 (-0.52%) ▼|PFE24.86+0.11 (+0.42%) ▲|PG147.65-1.49 (-1.00%) ▼|PLTR132.86-1.99 (-1.48%) ▼|PM189.68-3.04 (-1.58%) ▼|QCOM172.97+2.65 (+1.55%) ▲|RTX194.98+0.54 (+0.28%) ▲|SBUX104.48-0.33 (-0.31%) ▼|SCHW100.69-1.85 (-1.80%) ▼|SO93.68-0.78 (-0.83%) ▼|SPG226.54-1.65 (-0.72%) ▼|T22.09+0.14 (+0.62%) ▲|TMO523.98-2.25 (-0.43%) ▼|TMUS191.72-3.92 (-2.00%) ▼|TSLA380.14+10.57 (+2.86%) ▲|TXN293.49+9.42 (+3.32%) ▲|UBER71.53-0.65 (-0.89%) ▼|UNH434.26+12.71 (+3.02%) ▲|UNP294.41-1.85 (-0.62%) ▼|UPS115.91+2.76 (+2.43%) ▲|USB63.35+0.21 (+0.32%) ▲|V356.82-3.76 (-1.04%) ▼|VZ43.47-0.03 (-0.07%) ▼|WFC87.96+1.63 (+1.89%) ▲|WMT110.46-1.74 (-1.55%) ▼|XOM150.90+2.54 (+1.71%) ▲|AAPL327.36+0.77 (+0.23%) ▲|ABBV255.33+1.95 (+0.77%) ▲|ABT100.05-1.61 (-1.58%) ▼|ACN140.89-3.84 (-2.65%) ▼|ADBE226.71-8.03 (-3.42%) ▼|AMAT567.75+42.05 (+8.00%) ▲|AMD541.70+38.13 (+7.57%) ▲|AMGN364.49+0.32 (+0.09%) ▲|AMT163.75-3.32 (-1.98%) ▼|AMZN248.49-1.51 (-0.60%) ▼|AVGO386.17+8.01 (+2.12%) ▲|AXP351.03-0.90 (-0.26%) ▼|BA204.31-5.18 (-2.47%) ▼|BAC61.30+0.88 (+1.45%) ▲|BKNG177.97-1.48 (-0.82%) ▼|BLK1,040.96-13.15 (-1.25%) ▼|BMY60.47+0.31 (+0.51%) ▲|BNY158.67+1.74 (+1.11%) ▲|BRK-B489.69-1.56 (-0.32%) ▼|C132.90+4.18 (+3.25%) ▲|CAT889.71+25.41 (+2.94%) ▲|CL90.08-1.86 (-2.02%) ▼|CMCSA23.78-0.01 (-0.02%) ▼|COF206.12-0.65 (-0.31%) ▼|COP117.06+1.38 (+1.19%) ▲|COST931.02-4.78 (-0.51%) ▼|CRM170.24-3.55 (-2.04%) ▼|CSCO111.37+0.67 (+0.61%) ▲|CVS109.60+1.99 (+1.85%) ▲|CVX189.98+0.27 (+0.14%) ▲|DE589.47+3.47 (+0.59%) ▲|DHR178.69-22.42 (-11.15%) ▼|DIS96.50+0.09 (+0.09%) ▲|DUK125.59-0.26 (-0.21%) ▼|EMR139.43+2.85 (+2.09%) ▲|FDX314.80+8.58 (+2.80%) ▲|GD369.90-0.70 (-0.19%) ▼|GE340.98-0.33 (-0.10%) ▼|GEV1,083.23+4.05 (+0.38%) ▲|GILD129.80-3.41 (-2.56%) ▼|GM79.64+3.84 (+5.07%) ▲|GOOG348.19-3.18 (-0.91%) ▼|GOOGL348.89-3.10 (-0.88%) ▼|GS1,082.40+27.37 (+2.59%) ▲|HD330.63-2.41 (-0.72%) ▼|HON230.23+4.05 (+1.79%) ▲|IBM211.29-1.71 (-0.80%) ▼|INTC105.07+8.01 (+8.25%) ▲|INTU290.07-3.76 (-1.28%) ▼|ISRG357.26+4.09 (+1.16%) ▲|JNJ249.27+0.45 (+0.18%) ▲|JPM344.88+6.01 (+1.77%) ▲|KO82.09-0.04 (-0.04%) ▼|LIN506.73-5.32 (-1.04%) ▼|LLY1,163.31+16.41 (+1.43%) ▲|LMT505.40-4.14 (-0.81%) ▼|LOW203.42-1.29 (-0.63%) ▼|LRCX320.97+14.21 (+4.63%) ▲|MA538.78-8.66 (-1.58%) ▼|MCD265.19-2.45 (-0.92%) ▼|MDLZ59.79-0.49 (-0.80%) ▼|MDT82.31-0.98 (-1.18%) ▼|META647.02+1.17 (+0.18%) ▲|MMM169.90+10.79 (+6.78%) ▲|MO73.31-1.36 (-1.81%) ▼|MRK125.69+1.29 (+1.04%) ▲|MS215.36+4.42 (+2.10%) ▲|MSFT398.61-3.68 (-0.91%) ▼|MU974.66+109.20 (+12.62%) ▲|NEE87.92-0.08 (-0.09%) ▼|NFLX67.46-0.15 (-0.21%) ▼|NKE43.11-0.37 (-0.84%) ▼|NOW101.47-3.24 (-3.09%) ▼|NVDA206.09+2.81 (+1.38%) ▲|ORCL126.60+5.22 (+4.30%) ▲|PEP134.75-0.71 (-0.52%) ▼|PFE24.86+0.11 (+0.42%) ▲|PG147.65-1.49 (-1.00%) ▼|PLTR132.86-1.99 (-1.48%) ▼|PM189.68-3.04 (-1.58%) ▼|QCOM172.97+2.65 (+1.55%) ▲|RTX194.98+0.54 (+0.28%) ▲|SBUX104.48-0.33 (-0.31%) ▼|SCHW100.69-1.85 (-1.80%) ▼|SO93.68-0.78 (-0.83%) ▼|SPG226.54-1.65 (-0.72%) ▼|T22.09+0.14 (+0.62%) ▲|TMO523.98-2.25 (-0.43%) ▼|TMUS191.72-3.92 (-2.00%) ▼|TSLA380.14+10.57 (+2.86%) ▲|TXN293.49+9.42 (+3.32%) ▲|UBER71.53-0.65 (-0.89%) ▼|UNH434.26+12.71 (+3.02%) ▲|UNP294.41-1.85 (-0.62%) ▼|UPS115.91+2.76 (+2.43%) ▲|USB63.35+0.21 (+0.32%) ▲|V356.82-3.76 (-1.04%) ▼|VZ43.47-0.03 (-0.07%) ▼|WFC87.96+1.63 (+1.89%) ▲|WMT110.46-1.74 (-1.55%) ▼|XOM150.90+2.54 (+1.71%) ▲|
27.4 C
New York
Tuesday, July 21, 2026

Tag: tumor cells

newssourceFORcompanyinformationcontent1releasesmarket

Piston Bio Receives Endorsement from Leading Oncologists for its Tumor Antigen-Inducing Therapeutic

MORRISTOWN, N.J., July 15, 2025 (GLOBE NEWSWIRE) -- Piston Bio LLC, a biotechnology company developing both small molecules and biologics for the treatment of cancer, today announced that its scientific advisors have endorsed the potential of its next-generation therapeutic designed to induce tumor surface antigens and prevent immune escape. The endorsement follows a scientific advisory board meeting convened last month to review nonclinical data.

Anti-GPC3 Therapies Market Gains Traction with Key Players Advancing Pipeline for Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Gastric Cancer, and Others | DelveInsight

The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline...

Anti-GPC3 Therapies Market Gains Traction with Key Players Advancing Pipeline for Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Gastric Cancer, and Others | DelveInsight

The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline...

Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up

USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 10, 2025 /PRNewswire/ -- USA News Group News Commentary – Cancer rates are...

Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up

USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 10, 2025 /PRNewswire/ -- USA News Group News Commentary – Cancer rates are...

Bispecifics/BiTE Market Anticipates Impressive Growth Trajectory During the Forecast Period (2025-2034) Across 7MM Due to Their Expansion Beyond Oncology | DelveInsight

The bispecific antibody and BiTE market is witnessing robust growth driven by advances in immuno-oncology and rising demand for targeted cancer therapies. Key factors...

Bispecifics/BiTE Market Anticipates Impressive Growth Trajectory During the Forecast Period (2025-2034) Across 7MM Due to Their Expansion Beyond Oncology | DelveInsight

The bispecific antibody and BiTE market is witnessing robust growth driven by advances in immuno-oncology and rising demand for targeted cancer therapies. Key factors...

Dizal’s ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

ZEGFROVY is the only approved targeted oral treatment for NSCLC with EGFR exon20insApproval follows the U.S. FDA's Priority Review and is supported by the pivotal WU-KONG1 Part B study, in which...

I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study

DHODH Inhibitors Market Forecast to Reach New Heights by 2034 Owing to the Expanding Applications in Oncology and Autoimmune Diseases | DelveInsight

The DHODH inhibitor market is poised for steady growth, fueled by the rising burden of autoimmune and inflammatory diseases, along with increasing interest in...

DHODH Inhibitors Market Forecast to Reach New Heights by 2034 Owing to the Expanding Applications in Oncology and Autoimmune Diseases | DelveInsight

The DHODH inhibitor market is poised for steady growth, fueled by the rising burden of autoimmune and inflammatory diseases, along with increasing interest in...

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Latest Research Demonstrates Promising Improved Glucose Homeostasis by Reprogramming Alpha Cells AUSTIN, Texas, June 24, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a...

HER2-low Cancers Market Set to Register Immense Growth at a CAGR of 9.4% During the Study Period (2020-2034) | DelveInsight

The future of the HER2-low cancer treatment market is poised for significant transformation, driven by the approval of ENHERTU and the advancement of other...

Delta-like Ligand 3 Targeted Therapies Market is Predicted to Heat Up During the Forecast Period (2025-2034) Across 7MM Owing to a Robust Pipeline |...

The delta-like ligand 3 targeted therapies market is witnessing significant growth, driven by the rising incidence of small cell lung cancer (SCLC) and neuroendocrine...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTumor cells

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers